Frankfurt - Delayed Quote EUR

Palatin Technologies, Inc. (PTN.F)

0.1842

+0.0044

+(2.45%)

At close: April 24 at 6:44:44 PM GMT+2

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered melanocortin 4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide arm, bremelanotide alone, and tirzepatide

PR Newswire 7 days ago

PTN
Top Premarket Gainers

Third Harmonic Bio (THRD) shares rose 40% in recent Monday premarket activity, after saying its boar

PREMIUM
MT Newswires 10 days ago

AAPL

THRD

VERV
Palatin Appeals NYSE American Notice of Delisting

Palatin Technologies, Inc. (the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that it has formally appealed the NYSE Regulation determination to delist its common stock.

PR Newswire 10 days ago

PTN
Top Midday Decliners

Innovative Eyewear (LUCY) shares plunged 53% amid heavy trading after the company said Friday it is

PREMIUM
MT Newswires 13 days ago

LUCYW

PTN

TXN
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that on April 10, 2024, NYSE American LLC ("NYSE American") publicly announced and provided a notice to the Company that NYSE Regulation has determined to commence proceedings to delist the Company's common stock (the "Common Stock") from NYSE American. NYSE Regulation has

PR Newswire 14 days ago

PTN
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that data from the Phase 2b BREAKOUT study will be presented today at the National Kidney Foundation Spring Meeting in Boston, MA. The poster presentation titled Efficacy of Bremelanotide (BMT) to Stabilize Podocyte Function and Reduce Proteinuria in Adults with Diabetic Type II Nephropa

PR Newswire 14 days ago

PTN
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The Company reported positive topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory

PR Newswire 24 days ago

PTN
Palatin’s UC therapy prompts clinical remission in a third of patients

Results from the company’s Phase II trial also saw PL8177 elicit a clinical response in 77% of patients.

Clinical Trials Arena 27 days ago

PTN

GLDAF
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor (MC1R) agonist, in patients with active ulcerative colitis (UC). This study was designed to assess the safety, tolerability, and effectiveness of PL8177 when taken orally by adults with active UC.

PR Newswire 27 days ago

PTN
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug Administration (FDA) has granted "orphan drug" designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor (LEPR) deficiency, including obesity caused by this condition.

PR Newswire 30 days ago

PTN
Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now

Palatin Technologies (PTN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks last month

PTN
Q2 2025 Palatin Technologies Inc Earnings Call

Q2 2025 Palatin Technologies Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

PTN
Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...

Palatin Technologies Inc (PTN) reports reduced net loss and operational cash use, while advancing obesity treatment research and exploring partnership opportunities.

GuruFocus.com 2 months ago

PTN
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2024 and the completion of database lock for its Phase 2 obesity co-administration study with melanocortin 4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) du

PR Newswire 2 months ago

PTN
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets.

PR Newswire 2 months ago

PTN
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the "Regist

PR Newswire 2 months ago

PTN
Palatin concludes Phase II trial of combination therapy for obesity

The top-line outcomes are anticipated in the first quarter of 2025.

Clinical Trials Arena 2 months ago

PTN
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the completion of its Phase 2 BMT-801 clinical study of the co-administration of MC4R bremelanotide + GLP-1/GIP tirzepatide for the treatment of obesity. The last patient enrolled has completed their last visit. Final data collection and quality control will conclude shortly.

PR Newswire 2 months ago

PTN
Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system (MCRS), today provided an update on anticipated corporate milestones expected to occur in calendar year 2025.

PR Newswire 2 months ago

PTN
Palatin reports positive Phase 2b results in diabetic nephropathy

Palatin (PTN) announced topline data for the BREAKOUT study, a Phase IIb study of bremelanotide in diabetic kidney disease. The study showed that bremelanotide therapy for six months, in patients with established Type II diabetic nephropathy, resulted in positive and beneficial results for the majority of patients related to worsening kidney function and disease progression. Clinically meaningful endpoints included: 71% of patients achieved a greater than 30% reduction in the urine protein to cr

TipRanks 4 months ago

PTN

Performance Overview

Return	PTN.F	S&P 500 (^GSPC)
YTD	-82.94%	-6.75%
1-Year	-88.52%	+8.15%
3-Year	-98.20%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Palatin Technologies, Inc. (PTN.F)

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Top Premarket Gainers

Palatin Appeals NYSE American Notice of Delisting

Top Midday Decliners

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin’s UC therapy prompts clinical remission in a third of patients

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now

Q2 2025 Palatin Technologies Inc Earnings Call

Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Palatin concludes Phase II trial of combination therapy for obesity

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin reports positive Phase 2b results in diabetic nephropathy

Performance Overview